Fragile X syndrome, the most common form of inherited intellectual disability, may be unfolding in brain cells even before birth, despite typically going undiagnosed until age 3 or later.
Fragile X Syndrome
New research expands understanding of impact of rapamycin on fragile X syndrome
Fragile X syndrome (FXS) is the most common heritable form of intellectual and developmental disability. It is also the most common single genetic contributor to autism spectrum disorder (ASD).
The large scope of research on fragile X syndrome at the Waisman Center
Research studies at the Waisman Center cover both basic science and behavioral research on FXS, starting with the individual, up to the family unit, from childhood, and into old age.
Waisman investigator one of 12 to receive a Kellett Mid-Career Award
Xinyu Zhao, PhD, Waisman investigator and professor of neuroscience, was recently awarded a Kellett Mid-Career Award, among 11 others, by the Office of the Vice Chancellor for Research and Graduate Education.
Boys with fragile X syndrome + autism spectrum disorder and autistic boys show high rates of word omission during conversations
A recent study shows that boys with fragile X syndrome and co-occurring ASD (fragile X + ASD), and autistic boys have similar patterns of linguistic errors and omit more words in conversations compared to non-autistic boys.
A college degree may protect against neurodegeneration in genetically at-risk populations
Obtaining a college degree may be protective against neurodegenerative symptoms in women with an elevated genetic risk.
New NIH grant to study language use as potential predictor of neurodegenerative disorder in FMR1 premutation carriers
A new study will investigate if language differences can predict the development of a neurodegenerative disorder in people that carry a premutation of the gene FMR1.
Waisman center funds six internal grants to expand DEI efforts in research and clinical services
Diversity, equity, and inclusion (DEI) are critically important goals for the Waisman Center and UW Madison.
New Department of Defense grant to study fragile x syndrome in human cells
Xinyu Zhao, PhD, and Anita Bhattacharyya, PhD, will partner on research over the next four years to better understand the molecular underpinnings behind the diversity of FXS symptoms and how that diversity may inform the search for effective therapies.
Cancer drug may be treatment option for fragile X syndrome
A newer cancer drug may also be a treatment option for a leading intellectual and developmental disability. Fragile X syndrome (FXS) is the most common form of inherited intellectual disability.